Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression.
about
Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chainSirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.An animal model of chronic cyclosporine nephrotoxicity.Reducing adverse effects of immunosuppressive agents in kidney transplant recipients.Renal complications following heart transplantation in children: a single-center study.Comparison of survival of patients with heart and lung transplants on peritoneal dialysis and hemodialysis.Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression.A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.Progressive chronic kidney disease after pediatric lung transplantation.Kidney disease after heart and lung transplantation.Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial.Renal and liver transplantation for toxin-induced organ failure.Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant AloneDeferasirox nephrotoxicity-the knowns and unknowns.Chronic renal insufficiency in heart transplant recipients: risk factors and management options.Former smoking is a risk factor for chronic kidney disease after lung transplantation.First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation.Decline in renal function following thoracic organ transplantation in children.Outcomes following de novo CNI-free immunosuppression after heart transplantation: a single-center experience.Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction.Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.Outcomes after heart transplantation in patients with and without pretransplant renal dysfunction.Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule.Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy.Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicityThe natural history of renal function following orthotopic heart transplant
P2860
Q28343894-821F0B73-E41F-4991-8158-B39A4083A15CQ33376348-351C60F3-7F09-4E64-902B-73D4ED04A06EQ33693223-CDFDEBF6-EEBE-4AFC-A8EE-7C6C91A17D11Q34547749-7228FAFF-C05C-428B-8A43-EB72962BD8D2Q35072102-728B4CA2-92B0-4FA5-8F5D-F3CEEA76DDF1Q35106109-4870F18F-A69E-46B8-9820-9894D9302B3BQ35175413-A8D662F2-B13E-4495-A6BF-3C85561FFD16Q35835015-A5E5C05A-C0D3-4887-AE07-3CBA08DEA2D4Q36155845-45D7CE69-48DF-41EE-9A1C-EB0FAE2A60D0Q36422125-11430A7E-69A4-4AA1-8159-B68FEB18BCEAQ36498564-08C5E712-DE47-4E9E-8848-42176694A514Q36759257-7403F665-84D9-4C24-8C19-EEE9482C8D34Q36836432-E3078940-588E-4AED-A636-96CA28263FA6Q38232442-FD485374-7BDA-427A-9589-DB4F8CDAF3D6Q38240994-6EFC677F-67B7-4604-9222-F7ED584B0291Q39711763-DEFB9EB8-01E8-4F8F-AD73-A79AC06F0150Q43836681-D4CACA53-5EB4-45CD-8933-710F80355946Q44118346-2D889FD0-8DE5-4A9A-9159-C0237588EEE7Q44311127-9AEC95AA-8CCF-4437-AB74-59AFB920804DQ44412745-743EA74E-2AE2-4DD2-A826-591841976D8FQ44524563-4C378188-0194-4AEA-AE2D-94282489AAB2Q44779317-48EC1F0A-10EC-4E53-84F8-D9082EDABFCDQ46475765-B7386AB3-3E35-4D68-90DC-FDDD45131349Q51189916-170BBE45-0436-4487-A13F-77ECEBD97DEBQ51788749-9305A5E7-2E88-4CB0-A8A9-B6CBBA905387Q54989531-AA0F1E95-D4C8-4EFA-A562-E24FC287B799Q54989546-1304210F-7D22-4C4C-B442-5C1C73CBEE8C
P2860
Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Cyclosporine-associated end-st ...... on: incidence and progression.
@en
type
label
Cyclosporine-associated end-st ...... on: incidence and progression.
@en
prefLabel
Cyclosporine-associated end-st ...... on: incidence and progression.
@en
P2093
P1433
P1476
Cyclosporine-associated end-st ...... on: incidence and progression.
@en
P2093
P304
P356
10.1097/00007890-199703150-00009
P577
1997-03-01T00:00:00Z